Morgan Stanley Sees Big Potential in Kalaris’ Eye Drug TH103
Kalaris Therapeutics gets a boost as Morgan Stanley backs its longer-lasting eye drug, cutting injections for patients.
/ 1659 items
#XY↓
Abbott Beats Q1 Profit and Revenue Estimates, But Cuts 2026 Outlook After $23B Exact Sciences Deal
Abbott beat Q1 earnings, boosted by cancer diagnostics deal, but cut 2026 profit outlook due to acquisition costs.
Aligos Lands $445 Million China Deal for New Once-Daily Hepatitis B Pill
Aligos partners with Amoytop to bring a new hepatitis B drug to China, boosting cash and speeding access for millions of patients.
RFK Jr. Boosts Hims & Hers: FDA to Ease Restrictions on Popular Peptides
Hims & Hers Health jumps as FDA may ease rules on peptides, but experts warn they may be unsafe and lack proper testing.
PDS Biotech’s PDS01ADC Delivers Impressive 78% Response Rate in Advanced Colorectal Cancer Trial
PDS Biotech drug PDS01ADC improved tumor shrinkage and survival in colorectal cancer trials, showing strong early results.
Immutep Scores FDA Orphan Drug Win for Rare Cancer Treatment Efti
Immutep’s efti shows strong tumor shrinkage in rare cancer STS, earning FDA orphan status to speed development and approval.